Peter Stenvinkel Selected Research

Chronic Kidney Failure (Chronic Renal Failure)

01/2006	Serum albumin, C-reactive protein, interleukin 6, and fetuin a as predictors of malnutrition, cardiovascular disease, and mortality in patients with ESRD.
10/2005	Body fat mass and serum leptin levels influence epoetin sensitivity in patients with ESRD.
01/2005	Interleukin-1 gene cluster polymorphisms are associated with nutritional status and inflammation in patients with end-stage renal disease.
01/2005	Role of interleukin-1beta in the development of malnutrition in chronic renal failure patients.
01/2005	C-reactive protein in end-stage renal disease: are there reasons to measure it?
11/2004	Inflammation and oxidative stress in ESRD--the role of myeloperoxidase.
07/2004	Reduced gene expression of adiponectin in fat tissue from patients with end-stage renal disease.
02/2004	Associations between plasma ghrelin levels and body composition in end-stage renal disease: a longitudinal study.
06/2003	Plasma pentosidine is associated with inflammation and malnutrition in end-stage renal disease patients starting on dialysis therapy.
06/2003	Update on interleukin-6 and its role in chronic renal failure.
05/2003	A functional variant of the myeloperoxidase gene is associated with cardiovascular disease in end-stage renal disease patients.
09/2002	Plasma sulfur amino acids in relation to cardiovascular disease, nutritional status, and diabetes mellitus in patients with chronic renal failure at start of dialysis therapy.
06/2002	Influence of nutritional status on plasma and erythrocyte sulphur amino acids, sulph-hydryls, and inorganic sulphate in end-stage renal disease.
05/2002	Mortality, malnutrition, and atherosclerosis in ESRD: what is the role of interleukin-6?

Articles by Research Topic

Disease

14	Kidney Diseases (Kidney Disease) 09/2008 - 10/2003
14	Chronic Kidney Failure (Chronic Renal Failure) 01/2006 - 05/2002
12	Inflammation 06/2008 - 03/2003
7	Cardiovascular Diseases (Cardiovascular Disease) 09/2008 - 09/2002
4	Malnutrition 01/2006 - 05/2002
2	Atherosclerosis (Atheroma) 05/2002 - 02/2002
1	Albuminuria 07/2008
1	Diabetic Nephropathies (Diabetic Nephropathy) 05/2008
1	Syndrome 01/2008
1	Fibrosis (Cirrhosis) 01/2008
1	Insulin Resistance 03/2007
1	Vascular Diseases (Vascular Disease) 10/2006
1	Type 2 Diabetes Mellitus (MODY) 10/2005
1	Uremia 04/2005
1	Hepatitis C 12/2004
1	Hyperhomocysteinemia 09/2004
1	Diabetes Mellitus 09/2002

Drug/Important Bio-Agent (IBA)

5	Interleukin-6 (Interleukin 6)IBA 01/2006 - 02/2002
4	alpha-Fetoproteins (AFP)IBA 01/2008 - 01/2006
3	HomocysteineIBA 09/2008 - 01/2007
3	AdipokinesIBA 01/2008 - 01/2005
3	C-Reactive ProteinIBA 10/2006 - 01/2005
2	PTX3 proteinIBA 07/2008 - 09/2007
2	AdiponectinIBA 05/2008 - 07/2004
2	Biological Markers (Surrogate Marker)IBA 03/2008 - 09/2004
2	LeptinIBA 10/2005 - 10/2003
2	pentosidineIBA 12/2004 - 06/2003
2	Peroxidase (Myeloperoxidase)IBA 11/2004 - 05/2003
2	Amino Acids FDA Link 09/2004 - 06/2002
2	GhrelinIBA 02/2004 - 10/2003
1	S-AdenosylhomocysteineIBA 09/2008
1	Histidine (L-Histidine)FDA Link 06/2008
1	Nicotinamide PhosphoribosyltransferaseIBA 03/2008
1	sevelamer (RenaGel)FDA Link 01/2008
1	Glycoproteins (Glycoprotein)IBA 01/2008
1	Fibrinogen (Factor I)IBA 03/2007
1	8-oxo-7-hydrodeoxyguanosineIBA 11/2006
1	Serum AlbuminIBA 01/2006
1	Muscle Proteins (Muscle Protein)IBA 10/2005
1	Interleukin-10 (Interleukin 10)IBA 04/2005
1	Tumor Necrosis Factor-alpha (Tumor Necrosis Factor)IBA 04/2005
1	Interleukin-1beta (Interleukin 1 beta)IBA 01/2005
1	Interleukin-1 (Interleukin 1)IBA 01/2005
1	IronIBA 12/2004
1	calcium phosphateIBA 12/2003
1	CytokinesIBA 10/2003
1	Sulfur Amino AcidsIBA 09/2002

Therapy/Procedure

6	Peritoneal Dialysis 01/2008 - 03/2003
2	Renal Dialysis (Hemodialysis) 11/2006 - 10/2005